Compare Hilton Hotels Corporation Common Stock (HLT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Hilton Hotels Corporation Common Stock trades at $330.2 (market cap $73.82B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 14.7× Travere Therapeutics Inc. Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 139 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HLT | TVTX | |
|---|---|---|
Market Cap | $73.82B | $5.02B |
Volume | 1,126,885 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $67.52 |
52-Week Low | $256.96 | $26.79 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $86.84B | $5.15B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $329.59, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent revenue growth from $8.8B in 2022 to $12.0B in 2025, maintaining double-digit net income margins. Recent earnings beats and positive analyst sentiment (57% buy ratings) support the bullish case, though elevated valuation metrics (P/E 48.4) and negative shareholder equity warrant caution.
Outlook remains positive with Q3 2026 earnings anticipated on October 27, 2026, and consensus price target of $350 offering 6% upside. Key risks include high debt levels (debt-to-asset ratio 73.88% in 2025) and potential travel sector volatility. Institutional accumulation and strong cash flow generation provide fundamental support for long-term investors despite near-term overbought technical conditions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
